Jens Benn Sørensen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer
    Søren Astrup Jensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:1054-61. 2008
  2. pmc Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
    Søren A Jensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    BMC Cancer 9:25. 2009
  3. ncbi Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy
    Jens Benn Sørensen
    Department of Oncology, Finsen Centre National University Hospital, Copenhagen, Denmark
    Eur J Cardiothorac Surg 34:1090-6. 2008
  4. doi Current concepts in chemotherapy for malignant pleural mesothelioma
    Jens Benn Sørensen
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark
    Clin Respir J 2:74-9. 2008
  5. doi Pharmacokinetic evaluation of pemetrexed
    Jens Benn Sørensen
    FinsenCentre National University Hospital, Deptartment Oncology, 9 Blegdamsvej, DK Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 7:919-28. 2011
  6. doi Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies
    Jens Benn Sorensen
    Department Oncology, Finsen Centre National University Hospital, Copenhagen, Denmark
    Cancer 112:1600-6. 2008
  7. pmc Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
    J B Sørensen
    Department Oncology, Finsen Centre National University Hospital, 9 Blegdamsvej, Copenhagen DK 2100, Denmark
    Br J Cancer 99:44-50. 2008
  8. doi A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma
    Zarah Glad Zimling
    Department of Oncology, National University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark
    Cancer Chemother Pharmacol 70:743-54. 2012
  9. ncbi Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    J Cancer Res Clin Oncol 140:645-52. 2014
  10. doi 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
    Søren Astrup Jensen
    Department of Oncology 5073, Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:57-64. 2012

Collaborators

Detail Information

Publications33

  1. ncbi Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer
    Søren Astrup Jensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:1054-61. 2008
    ....
  2. pmc Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
    Søren A Jensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    BMC Cancer 9:25. 2009
    ..The association of MSI and MMR status with outcome and with thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression in colorectal cancer were evaluated...
  3. ncbi Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy
    Jens Benn Sørensen
    Department of Oncology, Finsen Centre National University Hospital, Copenhagen, Denmark
    Eur J Cardiothorac Surg 34:1090-6. 2008
    ..Staging is difficult and the accuracy of preoperative CT scan, 18F-FDG PET/CT scan (PET/CT), and mediastinoscopy is unclear. The objectives were to compare these staging techniques to each other and to surgical-pathological findings...
  4. doi Current concepts in chemotherapy for malignant pleural mesothelioma
    Jens Benn Sørensen
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark
    Clin Respir J 2:74-9. 2008
    ..The aim of this study was to provide an overview of the most active single agents and combination regimens in malignant pleural mesothelioma (MPM)...
  5. doi Pharmacokinetic evaluation of pemetrexed
    Jens Benn Sørensen
    FinsenCentre National University Hospital, Deptartment Oncology, 9 Blegdamsvej, DK Copenhagen, Denmark
    Expert Opin Drug Metab Toxicol 7:919-28. 2011
    ..Pemetrexed is a multi-targeted antifolate cytotoxic agent that has demonstrated activity in a number of very common cancer types including NSCLC in both first- and second-line settings and in the treatment of malignant mesothelioma...
  6. doi Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies
    Jens Benn Sorensen
    Department Oncology, Finsen Centre National University Hospital, Copenhagen, Denmark
    Cancer 112:1600-6. 2008
    ..The purpose was to evaluate prevention of oral mucositis (OM) using chlorhexidine compared with placebo and with oral cooling (cryotherapy) during fluorouracil (5-FU)-based chemotherapy in gastrointestinal (GI) cancer...
  7. pmc Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
    J B Sørensen
    Department Oncology, Finsen Centre National University Hospital, 9 Blegdamsvej, Copenhagen DK 2100, Denmark
    Br J Cancer 99:44-50. 2008
    ..6 to 40.6 + months). There were two CRs and 14 PRs (response rate 29.6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported...
  8. doi A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma
    Zarah Glad Zimling
    Department of Oncology, National University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark
    Cancer Chemother Pharmacol 70:743-54. 2012
    ..We further explored the possibility of combining markers into a treatment-response profile to increase the predictive power...
  9. ncbi Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    J Cancer Res Clin Oncol 140:645-52. 2014
    ..The current study aimed at investigating whether TS expression changes during non-pemetrexed chemotherapy of non-small cell lung cancer (NSCLC), thus making rebiopsy necessary for deciding on pemetrexed second-line treatment...
  10. doi 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
    Søren Astrup Jensen
    Department of Oncology 5073, Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:57-64. 2012
    ..This study aimed to elucidate the influence of 5-fluorouracil (5-FU)-based therapy on the vascular endothelium and its association with 5-FU-induced heart ischemia...
  11. ncbi ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial
    Adam Vilmar
    Department of Oncology 5073, Finsen Centre, National University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Eur J Cancer 46:1554-62. 2010
    ..Excision repair cross complementation group 1 (ERCC1) is a promising biomarker in advanced non-small cell lung cancer (NSCLC). However, current evidence regarding the impact of ERCC1 on toxicity and quality of life (QOL) is limited...
  12. ncbi Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis
    Søren Astrup Jensen
    Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark
    Med Oncol 23:521-31. 2006
    ..To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger...
  13. ncbi Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer
    Jacob Thomsen Lønborg
    Department of Oncology 5073, Finsen Centre, Rigshospitalet, University of Copenhagen, DK 2100 Copenhagen, Denmark
    Oncol Rep 18:1023-9. 2007
    ..Standard chemotherapy regimes seemed less effective on SBC than on CRC patients, and had a less favorable prognosis. However, reliable conclusions cannot be drawn from a small patient population, and multicentre studies are needed...
  14. doi Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial
    Adam Christian Vilmar
    Department of Oncology 5073, Finsen Centre, and Department of Pathology 5442, Diagnostic Center, National University Hospital, Copenhagen, Denmark
    Clin Cancer Res 17:5205-14. 2011
    ..Class III β-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role of TUBB3 in advanced NSCLC...
  15. ncbi Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment
    Jens Benn Sørensen
    Department of Oncology, Finsen Centre National University Hospital, Copenhagen, Denmark
    J Thorac Oncol 2:147-52. 2007
    ..Pemetrexed is active as first-line treatment of malignant pleural mesothelioma. The objective was to evaluate its activity as second-line treatment...
  16. ncbi The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil
    Søren Astrup Jensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark
    Int J Cancer 120:694-701. 2007
    ..This may be utilized in the selection of patients for treatment approaches and for decision on follow-up programs...
  17. doi Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature
    Adam Vilmar
    Department of Oncology 5073, Finsen Centre, National University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Lung Cancer 64:131-9. 2009
    ..Carboplatin has gained widespread use in the treatment of advanced NSCLC and its mechanisms of action are likely similar to that of cisplatin...
  18. doi Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle
    Søren Astrup Jensen
    Rigshospitalet, Copenhagen University Hospital, and Department of Oncology 5073, University of Copenhagen, 9 Blegdamsvej, Copenhagen, DK 2100, Denmark
    J Clin Oncol 28:5280-6. 2010
    ..Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart. This study aimed to clarify the pathophysiology, risk factors, and long-term effects of FU cardiotoxicity...
  19. doi Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 73:43-51. 2014
    ..Thus, the aim was to explore TUBB3 expression heterogeneity and changes during chemotherapy...
  20. ncbi Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma
    Claus Andrup Kristensen
    Department of Oncology, Copenhagen University Hospital Rigshospitalet, Denmark
    Radiother Oncol 92:96-9. 2009
    ..The present study reports and analyses the incidence of fatal pulmonary toxicity in patients treated at Rigshospitalet, Copenhagen...
  21. ncbi Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences
    Søren Astrup Jensen
    Department of Oncology, National University Hospital, 9 Blegdamsvej, Copenhagen, DK 2100, Denmark
    Acta Oncol 45:67-76. 2006
    ..68). Palliative capecitabine based therapy for advanced colorectal cancer should be considered also for elderly who are in good performance without major comorbidities...
  22. doi Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 73:131-7. 2014
    ..In addition, EGFR expression may also change during chemotherapy. The current study investigates the magnitude of these two issues...
  23. ncbi Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:289-99. 2012
    ..NSCLC is highly heterogeneous and biomarker expression may vary in different areas within the same tumor. This review explores the tumor heterogeneity and chemotherapy-induced changes in EGFR biomarker status in NSCLC...
  24. doi Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome
    Cecilia Bech
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark
    J Thorac Oncol 3:1359-60. 2008
    ..We therefore suggest that polyneuropathy is a possible paraneoplastic syndrome in MPM...
  25. doi Review on clinical trials of targeted treatments in malignant mesothelioma
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Copenhagen, Denmark
    Cancer Chemother Pharmacol 68:1-15. 2011
    ..This article is a comprehensive review of all clinical trials evaluating the effect of targeted treatments in MM...
  26. ncbi Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report
    Cecilia Bech
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark
    J Thorac Oncol 5:735-40. 2010
    ..pCR after chemotherapy is thus possible but rare, and we here present the cases from our institution together with a review on the literature available on the subject...
  27. ncbi [Screening for asbestos-related conditions]
    Charlotte Brauer
    arbejdsmedicinsk klinik, Glostrup Hospital, DK 2600 Glostrup
    Ugeskr Laeger 171:433-6. 2009
    ..Since mesothelioma is most often an occupational disease, these patients should be admitted to an occupational clinic for aetiological evaluation...
  28. doi Clinical impact of ki-67 labeling index in non-small cell lung cancer
    Jan Nyrop Jakobsen
    Department of Oncology, Finsencentre, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    Lung Cancer 79:1-7. 2013
    ..A predictive impact of ki-67 to treatment in NSCLC remains unclear...
  29. doi Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells--associations with histopathology and patients outcome
    Søren Astrup Jensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Eur J Cancer 46:3233-42. 2010
    ....
  30. ncbi Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer
    Adam Vilmar
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Anticancer Res 34:2991-6. 2014
    ..We explored its prognostic value using both quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC)...
  31. ncbi Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
    Søren Astrup Jensen
    Department of Oncology 5073, National University Hospital, 9 Blegdamsvej, 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 58:487-93. 2006
    ..5-fluorouracil (5-FU) and its prodrug capecitabine are cardiotoxic. This retrospective study aimed to identify risk factors and to give practical measures to make such chemotherapy feasible if cardiotoxicity occur...
  32. pmc Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib:
    Henrik H Rossing
    Laboratory of Molecular Pathology, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, 2100 Copenhagen, Denmark
    BMC Res Notes 6:489. 2013
    ....
  33. ncbi Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin
    Shoaib Afzal
    Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, 20 Tagensvej, 2200 Copenhagen, Denmark
    Cancer Chemother Pharmacol 69:301-7. 2012
    ....